Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%

🇩🇰 Investing.com (DK) —
Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%

AI Summary

Novo Nordisk raised its 2026 outlook as third-quarter sales of obesity treatments increased 22%. The update signals strong demand for the company’s obesity portfolio, though the headline does not specify the revised financial forecast.

Markets Health Novo Nordisk obesity treatments sales growth Q3 2026 outlook pharmaceuticals

Read original source →